SCHEMBL20093445

SCHEMBL20093445

Nc1ncnc2[nH]nc(-c3ccc(OCc4ccccc4)c(Cl)c3)c12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 9/20 0.50
ERBB2 P04626 9/20 0.50
PIK3CD O00329 3/20 0.50
PIK3CA P42336 3/20 0.50
PIK3CB P42338 3/20 0.50
PIK3CG P48736 3/20 0.50
PRKDC P78527 3/20 0.50
SRC P12931 3/20 0.50
ABL1 P00519 2/20 0.50
HCK P08631 1/20 0.50
KDR P35968 1/20 0.50
MTOR P42345 1/20 0.50
EPHB4 P54760 1/20 0.50
PI4KB Q9UBF8 1/20 0.50
PRMT5 O14744 1/20 0.43
GRM4 Q14833 1/20 0.43
MGAM O43451 1/20 0.41
GAA P10253 1/20 0.41
SI P14410 1/20 0.41
MGAM2 Q2M2H8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23735136 0.89 EGFR (0.42) EGFRERBB2PIK3CDPIK3CAPIK3CB
SCHEMBL13293328 0.86 ERBB2 (0.56) EGFRERBB2AURKA
SCHEMBL17626717 0.84 PIK3CD (0.47) EGFRERBB2PIK3CDPIK3CAPIK3CB
SCHEMBL19414295 0.82 SRC (0.47) EGFRPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL20793881 0.82 PIK3CD (0.60) EGFRPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL21048477 0.81 PIK3CD (0.67) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL20093481 0.79 KMO (0.46) EGFRPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL128454 0.78 PIK3CD (0.70) EGFRPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL15613541 0.77 BTK (0.60) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL16783578 0.76 PIK3CD (0.53) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11858907-B2 Kinase modulators RHIZEN PHARMACEUTICALS AG (CH) 2024-01-02 US disclosed
US-11858907-B2 Kinase modulators RHIZEN PHARMACEUTICALS AG (CH) 2024-01-02 US disclosed
US-20210401840-A1 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES RHIZEN PHARMACEUTICALS AG (CH) 2021-12-30 US disclosed
US-10442783-B2 2,3-disubstituted chromen-4-one compounds as modulators of protein kinases RHIZEN PHARMACEUTICALS SA (CH) 2019-10-15 US disclosed
US-10322130-B2 Substituted chromenones as modulators of protein kinases RHIZEN PHARMACEUTICALS SA (CH) 2019-06-18 US disclosed
US-20190105324-A9 SUBSTITUTED CHROMENONES AS MODULATORS OF PROTEIN KINASES RHIZEN PHARMACEUTICALS AG (CH) 2019-04-11 US disclosed
US-20180110783-A1 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES RHIZEN PHARMACEUTICALS SA (CH) 2018-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10442783-B2 2,3-disubstituted chromen-4-one compounds as modulators of protein kinases PIK3CB, PIK3CD, PDPK1 EGFR 929/4885ERBB2 211/4885PIK3CD 2/4885
US-20210401840-A1 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES PRKCA, PRKCH, PRKCB EGFR 1359/4885ERBB2 408/4885PIK3CD 47/4885
US-20190105324-A9 SUBSTITUTED CHROMENONES AS MODULATORS OF PROTEIN KINASES PRKCA, PRKCH, PRKAR2B EGFR 1502/4885ERBB2 433/4885PIK3CD 89/4885
US-20180110783-A1 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES PRKCA, PRKCH, PRKCB EGFR 1359/4885ERBB2 408/4885PIK3CD 47/4885
US-10322130-B2 Substituted chromenones as modulators of protein kinases MAP3K1, CSNK1A1, MAP3K2 EGFR 807/4885ERBB2 129/4885PIK3CD 148/4885
US-11858907-B2 Kinase modulators RPS6KA1, RPS6KA2, PRKAR2A EGFR 510/4885ERBB2 90/4885PIK3CD 103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.